Four-point scale for AMD risk

Article

Outlined of a four-point scale that may help to simplify the assessment of a patient's risk of developing age-related macular degeneration (AMD).

A presentation given at Hawaiian Eye 2007 meeting in January, outlined a four-point scale that may help to simplify the assessment of a patient's risk of developing age-related macular degeneration (AMD).

Frederick L. Ferris III, MD described how the scale was developed from the Age-Related Eye Disease Study (AREDS) clinical severity scale for AMD. This began life as a complex nine-step, five-year progression scale but, by focusing on simple clinical features, it was reduced to a five step, four-point model.

It focuses on large drusen (defined as drusen greater than 125 µm in diameter) and pigmentary changes. The old scale required grading of hyperpigmentation whereas the new scale just needs to know whether there is a pigmentation change or not.

Each eye is evaluated separately, with these factors in mind, and the scores combined. If large drusen are present, one point is counted and one point is also counted where there is a pigmentary change. There is a possible score of four points when the totals for each eye are combined.

Patients with a combined score of four points have a 50% risk of developing advanced AMD over five years, those with a score of three points have a 25% chance, those with a score of two have a 12% chance and those with a score of one have a 0.5% chance.

Dr Ferris suggested that this new scoring method could be used in future clinical trials as a tool for assessing eligibility.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.